Register for OBR daily


IMS_White_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CERU $4.22 0.2300 +5.76%
MGNX $21.00 0.9900 +4.95%
MACK $8.81 0.3900 +4.63%
ADXS $3.34 0.1000 +3.09%
CNDO $2.10 0.0600 +2.94%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

ECYT $6.12 -0.8701 -12.45%
KPTI $35.04 -3.3450 -8.72%
AGIO $60.85 -5.6460 -8.49%
GERN $2.02 -0.1400 -6.48%
CLVS $45.16 -2.9200 -6.07%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Penn Medicine and Wistar Receive $12 Million NCI Melanoma Grant to Help Fast Track Lab Discoveries into Treatments

(Penn Medicine) Sept 17, 2014 - Melanoma physicians and researchers from Penn Medicine and The Wister Institute have been awarded a prestigious $12.1 million SPORE grant from the National Cancer Institute.
read press release 



Lilly Sells Failed Cancer Drug Enzastaurin to Denovo

(PharmaTimes [UK]) Sept 16, 2014 - Eli Lilly has sold enzastaurin, a cancer treatment it abandoned development on, to San Diego-based Denovo Biopharma.
read article 



EMD Serono Teams Up with Sutro Biopharma to Work on Antibody Drug Conjugates

(Boston Globe) Sept 17, 2014 - EMD Serono Inc., a Rockland-based subsidiary of Germany’s Merck KGaA, and Sutro Biopharma said Wednesday that they have agreed to collaborate on developing antibody drug conjugates that target such diseases as cancer.
read article (free registration required) 



Sprague Study Estimates Number of U.S. Women with Mammographically-Dense Breasts

(University of Vermont) Sept 15, 2014 - A new study published in the September 2014 Journal of the National Cancer Institute (JNCI) estimates the number of women in the United States for whom breast density notification legislation would potentially impact.
read article 



ASCO 50th Anniversary Poll Names the Top 5 Advances from the Past 50 Years

(ASCO) Sept 17, 2014 - The American Society of Clinical Oncology (ASCO) today announced the “Top 5 Advances in 50 Years of Modern Oncology,” based on results of worldwide voting on CancerProgress.Net – ASCO’s interactive website documenting the history of progress against cancer.
read press release 



Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study

(Yahoo! Finance) Sept 16, 2014 - Oncolytics Biotech® Inc. today announced overall and KRAS-mutated patient data from a two-arm randomized phase 2 study of carboplatin, paclitaxel plus REOLYSIN® (test arm) versus carboplatin and paclitaxel alone (control arm) in the first line treatment of patients with recurrent or metastatic pancreatic cancer (NCI-8601).
read article 



Novartis Presents Oncology Research Advances with New Data on Zykadia(TM), Afinitor® and Key Pipeline Compounds at ESMO 2014

(NASDAQ) Sept 17, 2014 - Latest Zykadia data in patients with ALK+ non-small cell lung cancer, including updated brain metastases analysis from pivotal trial; final overall survival data from Phase III trial of Afinitor in advanced pancreatic neuroendocrine tumors (pNET); findings on Novartis pipeline compounds that target underlying cause of key diseases, including breast cancer, advanced basal cell carcinoma and melanoma.
read article 



Roche to Present Latest Oncology Advances During ESMO 2014 Congress

(Roche) Sept 17, 2014 - Presentations will include results from the Phase III coBRIM study of Roche’s investigational MEK inhibitor cobimetinib plus Zelboraf compared to Zelboraf alone, potentially paving the way for a new standard of care; final survival data from the Phase III CLEOPATRA study of the combination of Perjeta, Herceptin and chemotherapy, further confirming the potential of this regimen for people with HER2-positive metastatic breast cancer; and more.
read corporate press release 



Novel Drug Targeting Leukemia Cells Enters Clinical Trial

(UC San Diego Health System) Sept 16, 2014 - Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.
read press release 



Study Offers Clues to How Breast Implants May Cause Lymphoma

(University of Cambridge [UK]) Sept 16, 2014 - Researchers at the University of Cambridge have identified clues to explain how breast implants may, on very rare occasions, contribute to the development of lymphoma.
read article 



Genetic Discovery Yields Prostate Cancer Test, Promise of Future Therapy

(UPMC) Sept 15, 2014 - A genetic discovery out of the University of Pittsburgh School of Medicine is leading to a highly accurate test for aggressive prostate cancer and identifies new avenues for treatment.
read press release 



Study: New Radiosurgery Technology Provides Highly Accurate Treatment

(Henry Ford Health System) Sept 16, 2014 - A new stereotactic radiosurgery system provides the same or a higher level of accuracy in targeting cancer tumors – but offers greater comfort to patients and the ability to treat multiple tumors at once – when compared to other radiation therapy stereotactic systems.
read press release 



Study Adds to Cancer-fighting Promise of Combined Immunotherapy-radiation Treatment

(Science Codex) Sept 15, 2014 - A study in mice implanted with breast and melanoma cancers adds to a growing body of evidence that highly focused radiation – long thought to suppress immunity – can actually help boost the immune system's fight against cancer when combined with a new kind of immune-enhancing drug.
read article 



Fox Chase Study Helps Identify When and How Much Various Prostate Cancer Treatments will Impact Urinary and Sexual Functioning

(FCCC) Sept 16, 2014 - Men with prostate cancer may one day be able to predict when and how much various treatments will impact their urinary and sexual functioning, thanks in part to new findings presented at ASTRO.
read press release 



Fox Chase Study Questions the Benefit of Endocrine Therapy in Elderly Women with Low Risk Hormone Receptor Positive Breast Cancer

(FCCC) Sept 16, 2014 - Treatment with endocrine therapy and radiation therapy as part of breast conservation is the current standard of care for women with hormone-receptor positive (HR+) invasive breast cancer.
read press release 



Laser Focus on Treatment Costs vs. Value: Less Radiation for Elderly Women with Early Breast Cancer

(Yale News) Sept 16, 2014 - In a healthcare climate where the costs of treatment are increasingly weighed against potential benefit, a Yale study has found that radiation oncologists are using fewer or less-aggressive radiation procedures on elderly women with early-stage breast cancer.
read article 



Breast Cancer Patients Seek More Control Over Research Agenda

(NPR/Shots blog) Sept 16, 2014 - The federal government has poured more than $3 billion into breast cancer research over the past couple of decades, but the results have been disappointing. The disease remains a stubborn killer of women.
read article 



340B Drug Pricing Program Needs Updating, Says ASCO

(Medscape Medical News) Sept 15, 2014 - A 20-year-old drug pricing program needs to be revisited in order to ensure that it is still meeting the original intent of the legislation, says the American Society of Clinical Oncology (ASCO).
read article (free registration required) 



Gilead's Experimental Drug Fails Mid-stage Study

(Reuters) Sept 17, 2014 - Gilead Sciences Inc said its experimental drug did not significantly improve how long patients with a type of pancreatic cancer lived without the disease worsening.
read article 



Urine Test for HPV Works Well, Analysis Finds

(WebMD News/HealthDay News) Sept 16, 2014 - A simple urine test can routinely spot human papillomavirus (HPV), which is linked to the risk of cervical cancer, a new analysis found.
read article 



Gilead's Simtuzumab Fails Pancreatic Cancer Trial

(PharmaTimes [UK]) Sept 17, 2014 - Gilead Sciences’ simtuzumab is the latest compound to fail as a treatment for pancreatic cancer.
read article 



Switzerland Takes on Its Top Drugmakers in Price Row

(Reuters) Sept 16, 2014 - Switzerland, home to the world's two biggest drugmakers, might be expected to give them an easy ride. But Roche and Novartis are finding no immunity in their home market from a European-wide price squeeze.
read article 



Merck's Osteoporosis Drug Meets Primary Fracture Endpoints In Phase 3 Trial

(Forbes) Sept 15, 2014 - Merck's "heir to Fosamax," odanacatib, performs well in preventing fractures in a long, large trial with postmenopausal women over 65 suffering from osteoporosis.
read article 



AstraZeneca, Eli Lilly Form Alzheimer's Disease Treatment Alliance

(NASDAQ/Dow Jones Business News) Sept 16, 2014 - U.K.-based pharmaceutical company AstraZeneca PLC said Tuesday that it signed an agreement with U.S.- based Eli Lilly and Co. to develop and commercialize AZD3293, an oral beta secretase cleaving enzyme for the treatment of Alzheimer's disease.
read article 



New York Files an Antitrust Suit Against the Maker of an Alzheimer’s Drug

(New York Times) Sept 15, 2014 - New York State’s attorney general filed an antitrust lawsuit on Monday seeking to stop a pharmaceutical company from forcing patients with Alzheimer’s disease to switch to a new version of a widely used drug.
read article